Name:
EVAPORATE Trial Follow-Up
Description:
EVAPORATE Trial Follow-Up
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/98d07038-bd7e-4452-a5c2-763f5d712dad/thumbnails/98d07038-bd7e-4452-a5c2-763f5d712dad.jpeg?sv=2019-02-02&sr=c&sig=bpOlk9n8R%2FkL4rwpbF1%2FRyDmFx89s24IAaBvR0%2FGV7I%3D&st=2024-12-21T14%3A38%3A20Z&se=2024-12-21T18%3A43%3A20Z&sp=r
Duration:
T00H02M55S
Embed URL:
https://stream.cadmore.media/player/98d07038-bd7e-4452-a5c2-763f5d712dad
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/98d07038-bd7e-4452-a5c2-763f5d712dad/18778964.mp3?sv=2019-02-02&sr=c&sig=gZxFcnnBfaFqD80FYOZcmHByrnOuH0npbl3VJDz%2F8cI%3D&st=2024-12-21T14%3A38%3A20Z&se=2024-12-21T16%3A43%3A20Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's "The Heart Board Review" and other online resources available only through accesscardiology.com. >> The use of icosapent, which is a pure EPA, has resulted in proved cardiovascular outcomes. And the question is, by what mechanism is this agent able to do this? [ Music ] >> Hi. Dr. Bernie here, and welcome to Practice Impact Extra.
The REDUCE-IT trial, published in 2019, presented results of icosapent pure EPA on cardiovascular death, stroke, and revascularization in 8,000 patients. The icosapent group was noted to be superior to statin in patients with known coronary artery disease. At the virtual European Society of Cardiology meetings in August 2020, the EVAPORATE follow-up trial, the 18th-month follow-up trial, was presented and assessed the effect of icosapent on coronary atherosclerosis in patients with elevated triglycerides on statin therapy.
The goal was to assess the efficacy of icosapent in reducing plaque burden among patients with known angiographic coronary artery disease already on statins. Eighty patients are randomized either 4 grams per day of icosapent or a placebo. The inclusion criteria was that at the time of angiographic study, at least one angiographic stenosis of 20% or more was noted by CTA. Triglyceride levels were between 135 to 499 milliliters per deciliter.
So what were the outcomes? There was a change in the low-attenuation plaque line in the icosapent group. The secondary outcomes compared icosapent to placebo and noted a change in total plaque volume, a change in noncalcified plaque, a change in fibro-fatty plaque, as well as a change in triglycerides. What can we interpret from this trial? I think the cardiovascular benefit of icosapent in the REDUCE trial may be explained by the reduction of low-attenuation plaque line and total plaque volume as well as other plaque parameters noted on CTA.
Thank you for joining me and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw Hill. Subscribers to Access Cardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.